Saturday, January 31, 2026

North Korea Portrays “Family Image” Centered On Ju-ae… “Intent To Highlight Socialist Great Family”

Analysts note that the Korea-China summit avoided denuclearization talks, highlighting the need for dialogue to ease tensions on the peninsula.

The Easiest Way To Lose Investor Trust? Just Steal $6.7 Billion! BMS Masterclass In Bad Business

Bristol Myers Squibb faces a $6.7B lawsuit over alleged delays in drug approvals affecting former Celgene shareholders' payouts.

Samsung AI Forum 2025 Kicks Off, Focusing on Vertical AI Strategies in Semiconductors

Samsung AI Forum 2025 showcases advancements in AI, featuring keynotes from global experts and discussions on its impact in various industries.

Tag: Celltrion

North KoreaKoreaKimMilitarySouth KoreaAImarketrelationsInternational

Celltrion’s Zymfentra: How This Breakthrough Drug is Driving Record Sales

Celltrion expects record sales driven by Zymfentra's success, expanding into new biosimilars and CDMO business for future growth.

How Celltrion is Tackling U.S. Tariff Risks with New Production Facility in 2026

Celltrion addresses tariff risks by acquiring a U.S. facility, ensuring product supply and implementing strategies to mitigate uncertainties.

How Celltrion Plans to Expand Its Biosimilar Portfolio to 41 Products by 2038

Celltrion unveils its growth strategy at the JP Morgan Healthcare Conference, aiming to expand biosimilars and develop new drug pipelines.

K-Bio Targets the U.S. Market: Celltrion and Samsung Bioepis Close in on Originator Drugs

Celltrion and Samsung Bioepis are expanding in the U.S. market, showing strong growth in biosimilars like Zymfentra and Hadlima.

Celltrion’s Eydenzelt: How Strategic Patent Agreements Enable U.S. and European Market Entry in 2026

Celltrion's Eydenzelt secures global distribution via strategic patent agreements, aiming for swift market entry in the U.S. and Europe.

Celltrion’s ‘Psoriasis’ Biosimilar Poised to Challenge Big Pharma with Phase 1 Data

The EADV conference in Paris showcased Celltrion's biosimilar CT-P55, confirming its equivalence to Cosentyx in safety and pharmacokinetics.

Bio-Revolution: Celltrion’s $700M Biosimilar Is Reshaping the Global Drug Market

Celltrion's breakthrough in antibody biosimilars is transforming healthcare, enhancing access and innovation in treatment options.

Sales and Trust: How Celltrion is Revolutionizing the European Market Directly Connected

Celltrion leverages direct sales in Europe to enhance trust and supply stability while introducing biosimilars like Omlyclo for asthma treatment.

Celltrion’s Biosimilar Success in Europe Paves the Way for a US Market Takeover

Celltrion's booth at EADV 2025 highlighted biosimilar innovations, showcasing promising clinical trial results and expanding treatment access.

Saving Poverty vs Free Trade Society? How Celltrion’s Biosimilar Could Reshape the U.S. Healthcare Market

Professor Metz highlights biosimilars' potential to expand patient access to treatments, emphasizing Omliclo's impact at EADV conference.

FDA Ruling Paves Way for Pharmacy Substitution of Yuflyma for Humira

Celltrion's Yuflyma receives FDA approval for interchangeability with Humira, boosting market confidence and distribution in the U.S.

Europe Moves to Ease Biosimilar Rules, Boosting Asia’s Biopharma Giants

EMA's new guidelines aim to simplify biosimilar development, boosting Samsung Bioepis and Celltrion in Europe's growing market.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.